Search For "anti viral"
Glenmark introduces higher strength of FabiFlu to reduce pill burden of Co
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], Aug 6 (ANI): Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India.
Read More
Sun Pharma launches Favipiravir in India for Rs 35 per tablet
Updated : 5 years, 10 months ago IST
Mumbai (Maharashtra) [India], Aug 4 (ANI): Sun Pharmaceutical Industries said on Tuesday it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
Read More
Converge Biotech announces the launch of Vergiflu (Favipiravir 200 mg) in
Updated : 5 years, 10 months ago IST
Hyderabad (Telangana) [India] Aug 4 (ANI/BusinessWire India): Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India.
Read More
Cipla gets regulatory nod for launch of Ciplenza to treat mild to moderate
Updated : 5 years, 10 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Pharmaceutical major Cipla said on Friday it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza.
Read More
COVID-19: DCGI nod to Jubilant Generics to manufacture, sell remdesivir f
Updated : 5 years, 10 months ago IST
New Delhi [India], July 20 (ANI): The Drug Controller General of India (DCGI) has granted permission to pharma giant- Jubilant Generics Ltd to manufacture and market the anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, a senior health ministry offi
Read More
DCGI seeks clarification from Glenmark on its anti-viral favipiravir for u
Updated : 5 years, 10 months ago IST
New Delhi [India], July 19 (ANI): The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
Read More
Glenmark cuts COVID-19 drug Favipiravir price by 27 pc
Updated : 5 years, 10 months ago IST
Mumbai (Maharashtra) [India], July 13 (ANI): Glenmark Pharmaceuticals said on Monday it has cut the price of its anti-viral drug Favipiravir under the brand name FabiFlu for treatment of patients with mild to moderate COVID-19 by 27 per cent to Rs 75 per tablet.
Read More
Loyal Textile Mills Limited launched the world's first reusable PPE with T
Updated : 5 years, 10 months ago IST
Chennai (Tamil Nadu) [India] July 10 (ANI/NewsVoir): Loyal Textile Mills Limited today launched Viral Shield, a line of COVID-19 anti-viral, reusable Personal Protective Equipment (PPE), masks and protective fashion wear range.
Read More
DCGI instructs pharma giants manufacturing remdesivir to upload details of
Updated : 5 years, 10 months ago IST
New Delhi [India], July 9 (ANI): Witnessing the incidence of black marketing and overcharging of the remdesivir injection above MRP, the Drugs Controller General of India (DCGI) has directed all three pharma giants--Cipla, Hetero, and Mylan to upload the details of anti-viral Remedsivir drug
Read More
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per via
Updated : 5 years, 11 months ago IST
Bengaluru (Karnataka) [India], July 7 (ANI): Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 5 years, 11 months ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More
UK's RECOVERY trial found anti-viral HIV drug "ineffective"on COVID-19 pat
Updated : 5 years, 11 months ago IST
New Delhi [India], June 30 (ANI): Researchers from UK's RECOVERY trial (Randomised Evaluation of COVID-19 Therapy) have claimed to have found no benefit from anti-viral HIV drug-- 'lopinavir-ritonavir' administered in patients hospitalised COVID-19 patients.
Read More